These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1156 related articles for article (PubMed ID: 38054551)
1. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. van Geffen WH; Tan DJ; Walters JA; Walters EH Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551 [TBL] [Abstract][Full Text] [Related]
2. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566 [TBL] [Abstract][Full Text] [Related]
3. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Fukuda N; Horita N; Kaneko A; Goto A; Kaneko T; Ota E; Kew KM Cochrane Database Syst Rev; 2023 Jun; 6(6):CD012066. PubMed ID: 37276335 [TBL] [Abstract][Full Text] [Related]
4. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Oba Y; Keeney E; Ghatehorde N; Dias S Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694 [TBL] [Abstract][Full Text] [Related]
5. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242 [TBL] [Abstract][Full Text] [Related]
6. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102 [TBL] [Abstract][Full Text] [Related]
7. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Kew KM; Dias S; Cates CJ Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923 [TBL] [Abstract][Full Text] [Related]
8. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Nannini LJ; Lasserson TJ; Poole P Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099 [TBL] [Abstract][Full Text] [Related]
9. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Kew KM; Dahri K Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035 [TBL] [Abstract][Full Text] [Related]
10. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826 [TBL] [Abstract][Full Text] [Related]
11. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Farne HA; Cates CJ Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
13. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis. Oba Y; Anwer S; Patel T; Maduke T; Dias S Cochrane Database Syst Rev; 2023 Aug; 8(8):CD013797. PubMed ID: 37602534 [TBL] [Abstract][Full Text] [Related]
14. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Kew KM; Evans DJ; Allison DE; Boyter AC Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392 [TBL] [Abstract][Full Text] [Related]
15. Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease. Yang IA; Ferry OR; Clarke MS; Sim EH; Fong KM Cochrane Database Syst Rev; 2023 Mar; 3(3):CD002991. PubMed ID: 36971693 [TBL] [Abstract][Full Text] [Related]
16. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Kew KM; Seniukovich A Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010115. PubMed ID: 24615270 [TBL] [Abstract][Full Text] [Related]
17. Aclidinium bromide for stable chronic obstructive pulmonary disease. Ni H; Soe Z; Moe S Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126 [TBL] [Abstract][Full Text] [Related]